Kornel Pawlak, Dorota Danielak, Paweł Burchardt, Łukasz Kruszyna, Marta Karaźniewicz-Łada
{"title":"P2Y12基因多态性对经皮冠状动脉介入治疗后患者氯吡格雷治疗的影响。","authors":"Kornel Pawlak, Dorota Danielak, Paweł Burchardt, Łukasz Kruszyna, Marta Karaźniewicz-Łada","doi":"10.1080/14796678.2024.2363712","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> We aimed to define the influence of P2Y12 polymorphisms (rs6801273, rs2046934, and rs6809699), diabetes, hypertension, obesity, hypercholesterolemia, statins intake, and smoking habit on clopidogrel therapy in patients undergoing percutaneous coronary intervention.<b>Materials & methods:</b> We used PCR-RFLP and PCR-ASO for P2Y<sub>12</sub> genotype analysis. The effectiveness of the therapy was measured with the VerifyNow method and defined in platelet reactivity units.<b>Results:</b> Studied polymorphisms had no statistically significant influence on PRU before (PRU<sup>0</sup>) and 6 months (PRU<sup>6</sup>) after the procedure. H1/H1 diabetic carriers had significantly higher PRU<sup>6</sup> values than patients without diabetes. Obese H1/H2 subjects had significantly lower PRU<sup>6</sup> values than H1/H2 non-obese carriers.<b>Conclusion:</b> We found that obesity and diabetes may influence the long-term outcome of antiplatelet therapy.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"377-387"},"PeriodicalIF":1.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457605/pdf/","citationCount":"0","resultStr":"{\"title\":\"The influence of P2Y<sub>12</sub> gene polymorphisms on clopidogrel therapy in patients after percutaneous coronary intervention.\",\"authors\":\"Kornel Pawlak, Dorota Danielak, Paweł Burchardt, Łukasz Kruszyna, Marta Karaźniewicz-Łada\",\"doi\":\"10.1080/14796678.2024.2363712\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> We aimed to define the influence of P2Y12 polymorphisms (rs6801273, rs2046934, and rs6809699), diabetes, hypertension, obesity, hypercholesterolemia, statins intake, and smoking habit on clopidogrel therapy in patients undergoing percutaneous coronary intervention.<b>Materials & methods:</b> We used PCR-RFLP and PCR-ASO for P2Y<sub>12</sub> genotype analysis. The effectiveness of the therapy was measured with the VerifyNow method and defined in platelet reactivity units.<b>Results:</b> Studied polymorphisms had no statistically significant influence on PRU before (PRU<sup>0</sup>) and 6 months (PRU<sup>6</sup>) after the procedure. H1/H1 diabetic carriers had significantly higher PRU<sup>6</sup> values than patients without diabetes. Obese H1/H2 subjects had significantly lower PRU<sup>6</sup> values than H1/H2 non-obese carriers.<b>Conclusion:</b> We found that obesity and diabetes may influence the long-term outcome of antiplatelet therapy.</p>\",\"PeriodicalId\":12589,\"journal\":{\"name\":\"Future cardiology\",\"volume\":\" \",\"pages\":\"377-387\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457605/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/14796678.2024.2363712\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2024.2363712","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
The influence of P2Y12 gene polymorphisms on clopidogrel therapy in patients after percutaneous coronary intervention.
Aim: We aimed to define the influence of P2Y12 polymorphisms (rs6801273, rs2046934, and rs6809699), diabetes, hypertension, obesity, hypercholesterolemia, statins intake, and smoking habit on clopidogrel therapy in patients undergoing percutaneous coronary intervention.Materials & methods: We used PCR-RFLP and PCR-ASO for P2Y12 genotype analysis. The effectiveness of the therapy was measured with the VerifyNow method and defined in platelet reactivity units.Results: Studied polymorphisms had no statistically significant influence on PRU before (PRU0) and 6 months (PRU6) after the procedure. H1/H1 diabetic carriers had significantly higher PRU6 values than patients without diabetes. Obese H1/H2 subjects had significantly lower PRU6 values than H1/H2 non-obese carriers.Conclusion: We found that obesity and diabetes may influence the long-term outcome of antiplatelet therapy.
期刊介绍：
Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
